T. Rowe Price Funds SICAV - European Equity Fund Igq GBP 10Register to Unlock Ratings |
Performance History | 31/10/2024 |
Growth of 1,000 (GBP) | Advanced Graph |
Fund | - | - | - | - | 4.0 | |
+/-Cat | - | - | - | - | 0.2 | |
+/-B’mrk | - | - | - | - | -1.5 | |
Category: Europe Large-Cap Blend Equity | ||||||
Category Benchmark: Morningstar DM Eur TME NR EUR |
Key Stats | ||
NAV 22/11/2024 | GBP 10.38 | |
Day Change | 1.57% | |
Morningstar Category™ | Europe Large-Cap Blend Equity | |
IA (formerly IMA) Sector | Europe Including UK | |
ISIN | LU2714838484 | |
Fund Size (Mil) 21/11/2024 | EUR 72.79 | |
Share Class Size (Mil) 21/11/2024 | GBP 2.71 | |
Max Initial Charge | - | |
Ongoing Charge 30/08/2024 | 0.60% |
Investment Objective: T. Rowe Price Funds SICAV - European Equity Fund Igq GBP 10 |
To increase the value of its shares, over the long term, through growth in the value of its investments. |
Returns | ||||||||||||||||
|
Management | ||
Manager Name Start Date | ||
Tobias Mueller 01/07/2020 | ||
Inception Date 11/12/2023 |
Advertisement |
Category Benchmark | |
Fund Benchmark | Morningstar Benchmark |
MSCI Europe NR EUR | Morningstar DM Eur TME NR EUR |
Target Market | ||||||||||||||||||||
|
Portfolio Profile for T. Rowe Price Funds SICAV - European Equity Fund Igq GBP 10 | 31/10/2024 |
|
|
Top 5 Holdings | Sector | % |
Novo Nordisk AS ADR | Healthcare | 4.96 |
SAP SE | Technology | 3.81 |
ASML Holding NV | Technology | 3.75 |
ASTRAZENECA STOCK | 3.35 | |
Unilever CI | Consumer Cyclical | 2.86 |
Increase Decrease New since last portfolio | ||
T. Rowe Price Funds SICAV - European Equity Fund Igq GBP 10 |